Important parking update for Jonathan Lucas Parking Garage in Charleston.

Artificial Intelligence

Surgical Outcomes Research and Innovation Nucleus (SORIN) Supports Investigator-Initiated Clinical Trials

The Surgical Outcomes Research and Innovation Nucleus (SORIN) was formalized in 2019 and serves to foster the development, testing and implementation of innovative therapeutic and health services interventions aimed at improving outcomes in patients undergoing surgery at MUSC. With a major focus on expanding our industry-led and investigator-initiated clinical trials, we now have a new qualitative division,led by Saylor Hardin. She joined us upon completion of her MPH and has a robust background in public health, biostatistics andqualitative research. She is working closely with the thoracic oncology division to improve patient outcomes and optimize shareddecision making. Deanna DeHoff now leads the clinical trials. She has been crucial to the growth over the past four years and brings a deep understanding of clinical trial management to the team.

Sorin Leaders

From trial feasibility assessment to study close-out, their team provides a detailed and comprehensive array of support to conduct clinical trials in a safe and efficient manner. They also offer support in protocol development and post-trial publications for investigator-initiated, funded clinical trials. For more information, contact Morgan Overstreet, Director of Research Administration, at 843-792-8896 or overstrm@musc.edu.

clinical trialists resources

Clinical TrialsThe Department of Surgery has seen a steady increase in clinical trials that span most surgical disciplines, with significant growth in industry-sponsored research and investigator initiated clinical trials that show potential to create a paradigm shift in clinical care. 

It has an active portfolio of clinical research endeavors, including 44 enrolling studies and 16 in start-up or development, which span across most surgical disciplines housed within the Department of Surgery. In addition, the department has 12 clinical trials at the Hollings Cancer Center where our researchers are PIs or co-PIs. Our researchers are currently testing new drug therapies, devices, and cellular-based interventions designed to improve and extend the lives of South Carolinians seeking surgical care within our institution. 

We actively follow nearly 600 patients enrolled in our trials. We are currently testing new drug therapies, devices and cellular-based interventions designed to improve and extend the lives of South Carolinians seeking surgical care within our institution.

David Taber, Pharm.D., MS directs the clinical research group, which serves to foster the development, testing and implementation of innovative devices, therapeutics, and health services interventions aimed at improving outcomes in patients undergoing surgery at MUSC. While most clinical trials conducted in the department are industry-sponsored, growing the number of investigator-initiated clinical trials (IITs) can be dramatically more impactful, particularly at the local level. These trials stem from ideas generated by active investigators in our labs and clinical settings. They require significant resources since the sponsor investigator of the trial is not only sponsoring the study but also creating, coordinating, and carrying out the study, demonstrating collaboration, organizational capabilities, and institutional commitment.

Dr. Taber graduated cum laude and a member of the Dean’s list with a BS in Pharmacy from the State University of New York at Buffalo, one of the top pharmacy programs in the country. He was one of a handful of out-of-state applicants accepted into the post-baccalaureate PharmD program at the Medical University of South Carolina (MUSC). This program is known for its training opportunities with innovative clinical pharmacy practice. He graduated second in his class from MUSC, which aided in obtaining a post-doctorate pharmacy residency in transplant at the University of North Carolina (UNC) at Chapel Hill. Dr. Taber has approximately 15 years of post-residency experience providing pharmaceutical care to transplant patients. He has a strong record of collaborating in research endeavors surrounding the study of medication optimization in transplant recipients. Dr. Taber has a long-standing and deep seeded interest in conducting research. During his undergraduate education, he worked for Dr. Bauer analyzing the pharmaceutical properties of liposomal nitric oxide synthase inhibitors; through his doctorate training, he worked with Dr. White analyzing the pharmacokinetic and pharmacodynamic properties of the respiratory fluoroquinolones. Subsequently, Dr. Taber’s interest in conducting clinical research blossomed into a career passion through his clinical experiences with patient care. Dr. Taber’s academic training enabled him to gain a solid foundation in clinical pharmacy practice and collaborate with colleagues in clinical research.

The department has also prioritized the importance of high-impact clinical trials that show potential to create a paradigm shift in clinical care. Examples of high-impact clinical trials currently being conducted within the department include:

  •  SUMMIT Trial using Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation – Cardiothoracic Surgery; Marc R. Katz, M.D., MPH
  •  DeepView SnapShot Portable (DV-SSP): Device Training Study – Burn Surgery; Steven Kahn, M.D.
  •  BATwire - Percutaneous Implant Kit – Vascular Surgery & Cardiology: Jean Marie Ruddy, M.D.; Anne Kroman, DO, Ph.D. (Co-PIs)
  •  TRIOMPHE Study, using the NEXUS Aortic Arch Stent Graft System specifically engineered for minimally-invasive total arch repair – Vascular & Cardiothoracic Surgery; Ravi Veeraswamy, M.D. & Sanford Zeigler, M.D. (Co-PIs)
  • OCS Heart Perfusion Post-Approval Registry (Transmedics, Inc.) - Arman Kilic, M.D.
  • Shockwave use in aortic valve and aneurysm repair – Vascular Surgery; Mathew Wooster, M.D.
  • Telemedicine (TOBI) for pediatric burn patients – Pediatric Surgery; Aaron Lesher, M.D., MSCR
  • A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy ofSiplizumab in Combination with Belatacept and MPA Compared to Standard of CareImmunosuppression in de novo Renal Transplant Recipients (ASCEND) - Prabhakar Baliga, M.D.
  •  Nexobrid treatment for partial and full thickness burns – Burn Surgery; Steven Kahn, M.D.
  •  Comparison of surgery and medicine in diverticulitis – Colorectal Surgery; Thomas Curran, M.D., MPH
  •  A window trial on Boswellia, an extract from Frankincense, for breast cancer primary tumors – Surgical Oncology; Nancy KlauberDeMore, M.D.
  •  Increasing socioeconomically disadvantaged patients’ engagement in breast cancer surgery decision making through a shared decision making intervention – Surgical Oncology; Andrea Abbott, M.D. MSCR

Investigators within the Department of Surgery are nationally recognized in studying the causes and consequences of healthcare disparities in vulnerable patient populations, most notably African Americans.

Our researchers are conducting pioneering interventional studies with the goal of reducing the impact of race and socioeconomic status on health outcomes.

Within our clinical trials, we have a strong track record of enrolling patients that are not well represented in research. Often these patient populations are missing in clinical trials, and including these populations is of paramount importance to providing best clinical outcomes to all populations. Many of our other clinical trials, including oncology, cardiac surgery, and acute care surgery clinical trials, have similar populations.